The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on ...

AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...

Feds back AbbVie Colorado 340B fight, arguing state law conflicts with federal 340B program in a key 10th Circuit appeal.

The 340B Drug Pricing Program entitles participating hospitals and clinics (called covered entities) to purchase outpatient drugs at a substantial discount from manufacturers. Covered entities either ...

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

After federal judges blocked HHS’ 340B rebate pilot program from taking effect Jan. 1, HHS is discussing whether to reconsider the drug manufacturers’ plans, according to court documents. On Jan. 7, ...

Virginia state lawmakers who are tired of waiting are taking matters into their own hands during this year’s legislative ...

On July 31, 2025, the Health Resources and Services Administration (“HRSA”) announced the availability of a voluntary 340B Rebate Model Pilot Program (the “340B Rebate Pilot” or the “Pilot”) that ...

On December 29, 2025, Chief Judge Lance Walker of the U.S. District Court for the District of Maine granted the plaintiffs’ motion for a preliminary injunction in American Hospital Association v.

Good intentions alone are not enough in 340B. Let’s get informed. The good news is that the growing national scrutiny of how the 340B program operates should be seen not as a threat, but as an ...

The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs. The program has proved a flash point between drugmakers and providers, as ...